Home › Trials › NCT05376891

Registry for patients with advanced non-small cell lung cancer and specific genetic alterations

Disease Registry on Patients With Advanced NSCLC Harboring METex14 Skipping Alterations (MOMENT)

EMD Serono · NCT05376891

This study is collecting information from patients with advanced lung cancer who have a specific genetic change to see how they respond to different treatments over time.

Quick facts

Study typeObservational
Enrollment700 (estimated)
SexAll
SponsorEMD Serono (industry)
Locations64 sites (Fort Lauderdale, Florida and 63 other locations)
Trial IDNCT05376891 on ClinicalTrials.gov

What this trial studies

This multi-national disease registry aims to collect high-quality, standardized data on patients with advanced non-small cell lung cancer (NSCLC) who have mesenchymal-epithelial transition exon 14 (METex14) skipping alterations. The registry will gather information on demographic and clinical characteristics, treatment patterns, and outcomes over time, following participants as they receive routine clinical care. By capturing this data, the registry seeks to provide insights into the evolving treatment landscape and effectiveness of systemic therapies for this specific patient population.

Who should consider this trial

Good fit: Ideal candidates for this registry are individuals with advanced stage (stages IIIB-IV) NSCLC who have confirmed METex14 skipping alterations and are receiving systemic therapy.

Not a fit: Patients who are enrolled in other clinical trials may not benefit from this registry.

Why it matters

Potential benefit: If successful, this registry could enhance understanding of treatment outcomes and improve care strategies for patients with advanced NSCLC and METex14 alterations.

How similar studies have performed: Other disease registries have shown success in capturing valuable data and improving treatment understanding, making this approach both relevant and potentially impactful.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Participants who signed ICF
* Participants with advanced stage (stages IIIB-IV) NSCLC (all histologies) and Confirmed METex14 skipping alterations (by valid assay)
* Participants who are starting or are already being treated with systemic therapy

Exclusion Criteria:

* Participants who are enrolled in a clinical trial

Where this trial is running

Fort Lauderdale, Florida and 63 other locations

+14 more sites — see ClinicalTrials.gov for the full list.

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.

View on ClinicalTrials.gov →

Conditions: Cancer, Disease Registry, METex14 Skipping Alterations

Last reviewed 2026-05-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.